4D PHARMA PLC
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.4dpharmaplc.com
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Biological: MRx0005Biological: MRx0029
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT05832775
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- Biological: Avelumab 20 mg/mL Intravenous Solution (IV)
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT05107427
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT04363372
- Locations
- 🇬🇧
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Hypofractionated Preoperative Radiation
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 13
- Registration Number
- NCT04193904
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of MRx-4DP0004 in Asthma
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 34
- Registration Number
- NCT03851250
- Locations
- 🇬🇧
4D Site Leicester, Leicester, United Kingdom
🇬🇧4D Site Manchester, Manchester, United Kingdom
🇬🇧Bradford Teaching Hospital, Bradford, West Yorkshire, United Kingdom
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Other: PlaceboBiological: Blautix
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 366
- Registration Number
- NCT03721107
- Locations
- 🇺🇸
Connecticut Gastroenterology Clinical Research, Bristol, Connecticut, United States
🇺🇸Clinical Research Center of Florida, Pompano Beach, Florida, United States
🇬🇧CPS Research, Glasgow, United Kingdom
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
- Conditions
- OncologySolid TumorRenal Cell CarcinomaBladder CancerNon Small Cell Lung CancerMelanoma
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 63
- Registration Number
- NCT03637803
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Houston Methodist Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Other: ThetanixOther: Placebo
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 18
- Registration Number
- NCT02704728
- Locations
- 🇬🇧
Clinical Research Faciity, Glasgow, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, Birmimgham, United Kingdom